Rigel Pharmaceuticals | RIGL - Trade Creditors


Rigel Pharmaceuticals reported $3.85M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Agenus USD 85.29M 10.89M Sep/2025
Amgen USD 20.89B 1.25B Dec/2025
Anika Therapeutics USD 4.73M 39K Sep/2025
Arrowhead Research USD 32.94M 15.26M Dec/2025
AstraZeneca USD 25.28B 252M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Celldex Therapeutics USD 1.18M 3.09M Dec/2025
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Halozyme Therapeutics USD 20.9M 5.54M Dec/2025
Heron Therapeutics USD 12.02M 20K Sep/2025
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Karyopharm Therapeutics USD 5.39M 2.8M Sep/2025
Ligand Pharmaceuticals USD 3.24M 24.52M Dec/2025
MacroGenics USD 5.94M 1.28M Sep/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Pfizer USD 5.02B 142M Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Veracyte USD 4.59M 916K Dec/2025